Evaluating the 6-month formulation of paliperidone palmitate: a twice-yearly injectable treatment for schizophrenia in adults
Expert Rev Neurother. 2024 Apr;24(4):325-332. doi: 10.1080/14737175.2024.2325655. Epub 2024 Mar 6.ABSTRACTINTRODUCTION: Paliperidone Palmitate is the only antipsychotic that has been developed in three different intramuscular long-acting injectable (LAI) dosing regimen: monthly (PP1M), quarterly (PP3M), and from 2020 also twice-yearly (PP6M). The latter was approved for the maintenance treatment of adults with schizophrenia and clinically stabilized with PP1M or PP3M.AREAS COVERED: Data from studies evaluating efficacy in the maintenance treatment of schizophrenia with PP6M are reviewed. Since no post-marketing safety stud...
Source: Expert Review of Neurotherapeutics - March 6, 2024 Category: Neurology Authors: Giovanna Cirnigliaro Vera Battini Michele Castiglioni Marica Renne Giulia Mosini Stefania Cheli Carla Carnovale Bernardo Dell'Osso Source Type: research
